[ad_1]
European sources have announced that Johnson & Johnson is facing a problem with the supply of vaccine components, noting that the company refuses to comment on a possible delay in the supply of vaccines.
For its part, Johnson & Johnson have confirmed that the European Union will start receiving shipments of the vaccine in the second quarter of this year.
Since Johnson & Johnson revealed its vaccine and its effectiveness, estimated to be less than 72% versus around 95% for Moderna and Pfizer Point, health officials in the United States were concerned that some Americans would see the new vaccine as a lesser choice. . than others, but the first days Whoever proposed it showed something surprising and unexpected.
In one dose
Many people have expressed their desire to obtain it; Because they want one-dose relief, according to what was reported Thursday by the “New York Times”.
Public health officials have also shown enthusiasm for how quickly they can dispense a single dose, especially in remote communities who may not be able to easily access the vaccine.
In addition, this vaccine has many other benefits. Dr. Joseph Kanter, head of health in Louisiana, explained that a single dose would allow his condition to reduce the costs of personnel and operations related to the second dose.
It can also be given to people who may have difficulty reaching a second dose, such as those who are homeless or about to be released from prison, as several Oregon health officials explained, or groups of mobile farming communities with three working seasons. four weeks.
No fever or chills
For her part, North Carolina Health Minister Dr Mandy Cohen explained that the state’s major meat-packing plants, such as Smithfield and Tyson Foods, were interested in the Johnson & Johnson vaccine and consulted his administration.
And because the vaccine has fewer side effects than other options, it appeals to people who don’t want to risk missing a day of work to recover from possible symptoms such as chills or fever and arm pain.
Source link
